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a  b  s  t  r  a  c  t
We  previously  demonstrated  that  inﬂammatory  stress  impaired  cardiac  glucose  uptake,  using ﬂuo-
rodeoxyglucose  positron  emission  tomography/computed  tomography  (FDG-PET/CT)  by  showing  that  a
proportion  of patients  with  subtle  FDG  signals  was  remarkably  increased  compared  with  that  of  normal
subjects.  The  current  study  assessed  the  inhibitory  effects  of  cancer-associated  stress  on  cardiac  glucose
uptake in  female  cancer  patients,  and  compared  the  results  with  those  obtained  for  healthy  female  sub-
jects. Cardiac  glucose  uptake  was  decreased  in female  cancer,  as  indicated  by  the  signiﬁcantly  higher
number  of  patients  with  poor  FDG  uptake  and  the  lower  number  of patients  with  high FDG  uptake,  com-
pared  with  the  number  of  healthy  subjects  with  poor  and  high  FDG  uptake,  respectively.  These  results
suggest  that  cancer-associated  stress  inhibited  cardiac  glucose  utilization.  From  the  78 female  cancer
patients,  13  oophorectomized  patients,  who  underwent  repeated  postoperative  follow-up  examinations
by FDG-PET/CT  before  and  after  receiving  hormone  replacement  therapy  (HRT)  with  estrogen  derivatives,
were analyzed  to determine  the  effects  of  estrogen  on cardiac  glucose  uptake.  HRT  increased  a  proportion
of patients  with  high  FDG  signals  to comparable  in  healthy  subjects  with  high  FDG  uptake,  whereas  that
of patients  with  poor  FDG  uptake  decreased.  These  results  suggest  that  estrogen  can  improve  cardiac
glucose  uptake  in cancer-resected  and  oophorectomized  patients.
<Learning  objective:  This  study  presents  us  a new  point  of  view,  which  should  be taken  into  account
on the  pathophysiology  in  some  cardiovascular  diseases,  the  sex-differences  of energy  substrates  for  the
heart,  i.e.,  estrogen  or its derivatives  accelerates  the preference  of glucose  by the  heart.  Unfortunately,
a very  few  studies  have  studied  on this  issue,  e.g.,  effects  of sex-steroid  on  cardiac  uptake  of  energy
substrate,  and  therefore,  this  suggests  that cardiologists  do  not  focus  on this  issue.>
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In the previous study, we reported that systemic inﬂamma-
ion impairs cardiac glucose uptake, suggesting that in addition to
sychological stress, inﬂammatory stress itself remarkably affects
lucose utilization in cardiomyocytes. In that study, the number
f patients with inﬂammation, who exhibited poor cardiac ﬂuo-
odeoxyglucose (FDG) uptake, was signiﬁcantly higher than that of
ealthy controls with poor FDG uptake [1].  These results supported
he concept raised by Ansari [2] that the pathophysiology of Takot-
ubo cardiomyopathy may  be more complicated than expected
nd that in addition to the speculated pathophysiological factors
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including coronary microvascular dysfunction and reduced coro-
nary ﬂow, another key factor may  also be involved, namely the
poor utilization of energy substrates (glucose) necessary for opti-
mal  cardiac performance [1,2]. Inﬂammation and carcinogenesis
are well-known major stressors in the human body and many sub-
stances including cytokines, which have been implicated in the
development of cachexia, are found in the blood of cancer patients
independent of cancer stage. However, few studies have inves-
tigated the effects of cancer-associated stress on cardiac glucose
uptake and glucose metabolism. To investigate stressful conditions
other than inﬂammatory stress, the present retrospective study
focused on the effect of cancer-associated conditions on cardiac
glucose utilization.
One of the characteristic features of Takotsubo cardiomy-
opathy is female predominance. Therefore, many animal and
human studies have been conducted to determine the protective
vier Ltd. All rights reserved.
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Fig. 1. Cardiac glucose uptake is decreased in cancer patients compared with that
in  healthy, age-matched female controls. The prevalence of a PET score 0 is higher
selected from those evaluated in the ﬁrst part of the study. Post-
operatively PET/CT examinations were repeatedly performed both
before and after HRT with estrogen derivatives. The effects of HRT
in these 13 patients were evaluated using PET/CT. As shown in
Fig. 2. In 13 female patients who underwent cancer resection followed by oophorec-Y. Kakinuma et al. / Journal of
ffects of estrogen and its derivatives against stress-induced car-
iomyopathy [3–7]. These studies have mainly focused on the
nhibitory effects of estrogen on cell death caused by reactive
xygen species and on hypothalamo-sympatho-adrenal outﬂow.
he effects of estrogen on enhanced gene expression of car-
ioprotective molecules have also been covered. However, the
ffects of estrogen on the regulation of cardiac energy metabolism,
specially on cardiac glucose uptake, remain to be elucidated.
n this study, the extent of cardiac glucose uptake was  deter-
ined in female cancer patients and compared with that in
pparently healthy female subjects. Then, the effects of estrogen
upplementation on cardiac glucose uptake were evaluated using
8F-ﬂuorodeoxyglucose positron emission tomography/computed
omography (FDG-PET/CT) imaging.
ethods
The data obtained by FDG-PET/CT imaging, a speciﬁc method of
valuating cardiac glucose utilization, are known to be profoundly
ffected by variation in glucose levels. To overcome data variabil-
ty as much as possible, examinations at our university hospital are
outinely performed after patients have fasted for more than 12 h.
o investigate the effects of cancer-related stress on cardiac glu-
ose uptake, we examined PET scores of 78 female cancer patients
n = 78; age, 47 ± 12 years) with no past history of diabetes mellitus
DM). The PET score, developed for semi-quantitative assessment
f cardiac glucose uptake in our previous study [1],  was  also used
n the present study. These scores were assigned according to the
evel of FDG uptake, as follows: score 0, a faint FDG signal in the
ntire transverse section of the mid-portion of the left ventricle,
hich demonstrates a ring form; score 1, a signal with characteris-
ics intermediate to those representing scores 0 and 2; and score 2,
 homogeneous, intense signal throughout the ring. Our previous
tudy clearly demonstrated that despite adjustment for the vari-
bility in FDG signals, PET scores of 0 were always observed in a
roportion of normal controls (10–15%). The locations of cancer in
he study patients were as follows: ovary (n = 14), uterine cervix
n = 15), uterus (n = 4), breast (n = 2), colon (n = 5), stomach (n = 7),
sophagus (n = 2), thyroid (n = 2), blood (n = 3), and miscellaneous
ites (n = 24). Patients with end-stage cancer were not included. For
omparison, PET/CT examinations were also performed in a con-
rol group including 121 age-matched (51 ± 10 years) apparently
ealthy subjects, who reported no history of inﬂammatory diseases,
eart diseases, or DM in a medical questionnaire and underwent
ET/CT to exclude malignancy as part of personally requested
ealth check-ups during the same period. Before PET/CT examina-
ion, written informed consent, which was approved by the ethics
ommittee of Kochi Medical School Hospital, was obtained from all
he patients and healthy subjects.
In another retrospective study, we also focused on the effects
f hormone replacement therapy (HRT) with estrogen derivatives,
hich was postoperatively started in 13 oophorectomized patients,
ho had been treated for ovarian or uterine cervical cancer. These
atients were among those included in the ﬁrst part of the study
valuating the effects of stress on cardiac glucose uptake. These
atients had no history of coronary, infectious, metabolic diseases,
r chronic renal failure. No patients were identiﬁed to show car-
iac dysfunction. The chemotherapy regimens applied to these 13
atients included carboplatin, cisplatin, paclitaxel, vincristine, and
itomycin C. No anthracyclines, which are well-known to be car-
iotoxic, were included. HRT for these oophorectomized patients
as usually started during chemotherapy. Therefore, PET/CT was
erformed to evaluate cardiac glucose uptake rather during ongo-
ng or following chemotherapy.
Statistical analysis was performed as follows. Differences in the
roportional trend in PET scores between the controls and cancerwhile that of score 2 is reciprocally lower in cancer patients than in healthy controls.
PET,  positron emission tomography. (For interpretation of the references to color in
the  text, the reader is referred to the web version of the article.)
patients were evaluated by using the chi-square test, and changes in
PET scores in the cancer patients before and after HRT were assessed
by the Wilcoxon t-test. In both tests, differences were considered
to be signiﬁcant at p < 0.05.
Results
Fig. 1 shows that in the female cancer patients (pink column), the
prevalence of PET scores 0, 1, and 2 were 50.0%, 24.4%, and 25.6%,
respectively. In contrast, in the age-matched, apparently healthy
females (n = 121) (blue column), PET scores of score 0, 1, and 2 were
15.7%, 32.2%, and 52.1%, respectively. These results indicated that
the number of cancer patients with a PET score of 0 was signiﬁcantly
higher than the number of controls with the same score (15.7% vs.
50.0%; p < 0.01; Chi-square test). On the other hand, score of 2 was
more frequent in the controls than in the cancer patients (52.1% vs.
25.6%; p < 0.01; Chi-square test).
As previously mentioned, 13 female patients (age, 49 ± 10 years;
red column) suffering from ovarian or uterine cervical cancer,
who underwent bilateral oophorectomies, were retrospectivelytomy, restoration of glucose uptake levels following hormone replacement therapy
(HRT) with estrogen derivatives was exhibited. After HRT  the prevalence of a PET
score 0 is lower while that of score 2 is higher. PET, positron emission tomography.
(For interpretation of the references to color in the text, the reader is referred to the
web version of the article.)
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ig. 2, the prevalence of patients with scores 0, 1, and 2 were 30.8%
n = 4), 30.8% (n = 4), and 38.5% (n = 5), respectively (red column).
efore HRT, these 13 patients showed an increased prevalence of
he score 0 and a reciprocally decreased prevalence of the score 2
ompared with that in the controls (blue column). After HRT, how-
ver, the prevalence of score 0 decreased from 30.8% to 0%, while
hat of score 2 increased from 38.5% to 61.5% in the cancer patients
Fig. 2, light blue column; p < 0.05; Wilcoxon t-test), thus becoming
omparable between the cancer patients and controls.
iscussion
The present study suggests that female cancer patients have
mpaired cardiac glucose uptake, suggesting that cancer-associated
tress suppresses efﬁcient cardiac glucose utilization. This was  indi-
ated by differences in the prevalence of PET scores between 78
emale cancer patients and 121 age-matched, healthy female con-
rols (Fig. 1). This study also suggests that estrogen is involved in
he restoration of cardiac glucose uptake (Fig. 2). Studies inves-
igating the risk factors of cardiovascular diseases have revealed
hat women in the reproductive phase of their life are at a low
isk of cardiovascular diseases. However, onset of menopause and
oss of ovarian function are associated with a signiﬁcant increase
n the prevalence of diseases such as coronary heart disease. Many
tudies have asserted the beneﬁcial and cardioprotective effects
f estrogen, including anti-apoptosis, anti-cardiac remodeling, and
odulation of calcium signaling. However, studies have not yet
onﬁrmed the efﬁcacy of HRT in preventing cardiovascular events.
ome controversy exists over the modulating effects of estrogen
n cardiac glucose metabolism in human hearts. FDG-PET/CT may
e useful in fully investigating these effects. One study found that
lucose utilization was not affected by estrogen, but fatty acid uti-
ization was affected by estrogen [8]. The present retrospective
tudy despite its small patient population and endogenous nature
uggested a novel pathophysiological mechanism of Takotsubo
ardiomyopathy other than conventional stress, which includes
sychological stress that directly activates catecholamine release.
Takotsubo cardiomyopathy was initially observed in typical
ircumstances of psychological stress and was represented by a
atecholamine surge. However, cases of Takotsubo cardiomyopa-
hy in the absence of psychosocial stress have also been reported.
n those cases despite difference in underlying diseases, the com-
on  feature of impaired cardiac glucose uptake was identiﬁed
y FDG/PET analysis [9,10].  Cancer-associated cachexia induces
 cytokine storm; but in contrast, elevated catecholamine levels
ause insulin resistance. On a superﬁcial level, the pathophysio-
ogical features of these conditions seem to be distinct. However,
ased on the results of the present FDG study, impaired cardiac
lucose utilization may  be a common downstream phenomenon
hared by conditions of different etiology.
Cancer may  be a speciﬁc stressor that impairs cardiac glucose
ptake in a manner similar to inﬂammation, that is, through the
ctivity of proinﬂammatory cytokines, including tumor necrosis
actor, as previously reported in our study [1].  Impaired glucose
tilization may  cause inadequacies in cardiac glucose metabolism
hen the demand for glucose is abrupt, as in the case of patho-ogical insults. HRT may  therefore be beneﬁcial for the restoration
f impaired cardiac glucose metabolism. Considering the present
esults and the fact that Takotsubo cardiomyopathy predominantly
ccurs in females, we suggest that estrogen enhances glucose
[logy Cases 7 (2013) e24–e26
utilization and provides adequate energy substrates to cardiomy-
ocytes. These mechanisms may  cause resistance of cardiomyocytes
to apoptosis. Therefore, estrogen may  play a pivotal role in arresting
the development of Takotsubo cardiomyopathy in female cancer
patients.
According to the results of the current study, HRT contributes
to enhanced glucose uptake. This result in patients with tumor
resection followed by oophorectomies suggests that estrogen
plays a positive role in cardiac glucose uptake. This suggestion
is also supported by the fact that Takotsubo cardiomyopathy is
more often seen in middle-aged, especially menopausal females.
In addition, cardiomyopathy observed in oophorectomized rats
with restraint stress was partially reversed by estrogen ther-
apy [3,5]. A cascade connecting estrogen with enhanced glucose
uptake may  occur during the process of glucose utilization in the
heart.
The small population in this study is a limitation that must be
overcome in a future study by enrolling more patients to con-
ﬁrm the hypothesis suggested here. Future in vitro studies will
investigate the direct effects of estrogen on glucose utilization of
cardiomyocytes.
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